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The current study aimed to assess the efficacy and safety of buprenorphine maintenance for 
the treatment of illicit opioid dependence during pregnancy. Parameters investigated 
assessed pregnancy progression and Neonatal Abstinence Syndrome (NAS) compared to 
methadone maintenance and non-opioid exposed control pregnancies. This is the first study 
to present results comparing the two treatment groups to a control population. The trial was 
a prospective, non-randomised, open-label, flexible dosing study (n=25 for each group). 
Women were recruited up to a gestational age of 28 weeks and their infants observed 
postnatally for 4 weeks. Methadone and buprenorphine doses did not change significantly 
from recruitment to delivery and were 48.40±5.95 mg.dail and 7.46±O.84 mg.dai\ 
respectively at delivery. Both SUbjective and objective measures of maternal withdrawal 
were significantly lower for buprenorphine compared to the methadone group (p<O.Ol and 
p<O.05, respectively) at the sub-optimal does observed in this study. Direct drug effects 
were similar between methadone and buprenorphine groups and did not change over the 
course of pregnancy. Additional substance use during pregnancy was significantly higher 
for methadone and buprenorphine groups compared to controls but was not significantly 
different between each other. Patterns of maternal symptom complaints during pregnancy 
were higher for methadone and buprenorphine compared to controls but were not 
significantly different to each other and raised several issues regarding maternal health, and 
re-dosing in the antenatal period. Obstetric complications in the antenatal period and 
during labour and delivery were similar between the three groups. There was no significant 
difference between the three groups for infant gestational age at delivery or their Apgar 
scores. However, methadone exposed infants were significantly smaller than control 
infants (birth weight p<O.05, body length p<O.05, head circumference p<O.05) while 
buprenorphine exposed infants did not differ to controls. There was no significant 
""' 
difference between methadone and buprenorphine exposed infants for the percentage of 
infants who required pharmacological treatment to control NAS (methadone 60%, 
buprenorphine 48%). However, significantly less morphine was required to control NAS in 
buprenorphine compared to methadone exposed infants (methadone: 40.07 ± 3.95 mg, 
buprenorphine: 22.77 ± 4.29 mg; p<0.05) and may have been due to reduced placental 
transfer of buprenorphine. The current study observed buprenorphine to be at least as 
efficacious as methadone for the treatment of opioid dependence during pregnancy while 
minimising NAS. 
